Ube Industries Ltd

UBE is looking for out-licensing opportunities of their assets.

SECTOR: Pharmaceutical / Chemical
KEY WORDS: Small Molecule, Drug Discovery, Out-licensing

Company Activity Description:

· Ube Industries has been one of the leading chemical companies in Japan since over a century ago.

· In the drug discovery, Ube has engaged in the research and development of NMEs such as Efient (prasugrel, an anti-platelet agent), Talion (bepotastine, an anti-allergic agent) and Calblock (azelnidipine, an anti-hypertensive agent), which were discovered by the unique medicinal chemistry and efficacious pharmacological evaluation, and the cooperation with pharmaceutical partners.

· Presently, they are focusing on areas of fibrosis/chronic inflammation, cancer/autoimmune diseases and complications of cardiovascular and metabolic disorders.


Type of Partnership Sought:

1.License agreement


Additional information:

Detail of partnership sought:

They are looking for out-licensing opportunities of the following products to pharmaceutical or biopharma companies.

  1.  UD-014: SSAO/VAP1 inhibitor

A novel, small molecule, semicarbazide-sensitive amine oxidase (SSAO)/vascular adhesion protein-1 (VAP-1) inhibitor at the pre-clinical stage for NASH and diabetic nephropathy. The compound shows a compelling efficacy in a STAMTM mouse NASH model and a ZSF1 rat diabetic nephropathy model by uniquely protecting from oxidative-stess induced endothelial injury.

Click on images for details.



  1. UD-017: CDK7 inhibitor

A novel, reversible, cyclin dependent kinase 7 (CDK7) specific inhibitor at the pre-clinical stage for cancer (best-in-class). The candidate compound shows a broad spectrum of anti-tumor activity in cancer cells and a potent oral activity in multiple myeloma and ovarian xenograft models in mice. The program is now ready to GLP studies.

Click on images for details.


Company website


Contact details: 

EU-Japan Centre for Industrial Cooperation / info-eu@een-japan.eu